Compare Cassava Sciences Inc (FLNA) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Toronto-Dominion Bank — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Toronto-Dominion Bank trades at $121.35 (market cap $199.91B). The key difference: Toronto-Dominion Bank is far larger — about 4186.6× Cassava Sciences Inc's market cap, and Toronto-Dominion Bank pays a 2.64% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TD | |
|---|---|---|
Market Cap | $47.75M | $199.91B |
Sector | Health | Financials |
52-Week High | $4.64 | $124.80 |
52-Week Low | $0.87 | $72.85 |
Enterprise Value | -$34.93M | — |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
TD stock trades at $121.31, up 0.11% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $1.74, exceeding the $1.63 estimate, and maintains a strong net income margin of 23.38%. Analyst consensus is positive with 9 buy ratings and no sell ratings among 17 analysts. Recent news highlights value comparisons with peers and dividend stability.
Outlook remains favorable due to consistent earnings performance and robust profitability, though risks include high debt levels and potential regulatory scrutiny. The stock's valuation at a P/E of 19.95 is reasonable relative to historical margins, supporting a cautious bullish view for long-term investors seeking dividend income and steady growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
